DOPAMINE HYDROCHLORIDE

Clinical safety rating: safe

Animal studies have demonstrated safety

How it works

Dopamine hydrochloride is a direct precursor of norepinephrine and acts as an agonist at dopaminergic D1 and D2 receptors, as well as β1-adrenergic and α1-adrenergic receptors at higher doses. It increases cardiac contractility and heart rate via β1 agonism, and causes vasoconstriction via α1 agonism. At low doses, it dilates renal and mesenteric vasculature through D1 receptor activation.

What the body does with it

Metabolism	Primarily metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites. Small amounts are converted to norepinephrine.
Excretion	Dopamine is primarily metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to homovanillic acid (HVA) and other inactive metabolites. Approximately 80% of a dose is excreted in urine within 24 hours, mainly as HVA and conjugated metabolites; less than 10% is excreted unchanged. Biliary/fecal elimination is negligible.
Half-life	The terminal elimination half-life of dopamine is approximately 2 minutes after intravenous administration. This short half-life necessitates continuous infusion to maintain steady-state concentrations. Clinical context: the rapid offset allows for quick titration of hemodynamic effects.
Protein binding	Dopamine is approximately 40-60% bound to plasma proteins, primarily albumin.
Volume of Distribution	The volume of distribution (Vd) of dopamine is 0.8-1.2 L/kg, indicating distribution into total body water with some tissue binding. Clinical meaning: loading doses may be required to achieve steady-state rapidly, but due to short half-life, continuous infusion is standard.
Bioavailability	Oral bioavailability is <5% due to extensive first-pass metabolism, thus intravenous administration is required. Bioavailability via other routes is negligible.
Onset of Action	Intravenous: Onset of action occurs within 2-5 minutes. No other routes are clinically used due to extensive first-pass metabolism; onset via oral is not applicable.
Duration of Action	Intravenous: Duration of action is approximately 10 minutes after discontinuation of infusion, correlating with the short half-life. Hemodynamic effects resolve rapidly upon cessation.

Classification & Brands

Dosing & administration

1-5 mcg/kg/min IV continuous infusion for low dose; 5-10 mcg/kg/min IV for intermediate; 10-20 mcg/kg/min IV for high dose.

Dosage form	INJECTABLE
Renal impairment	No specific GFR-based dose adjustment required; drug is primarily metabolized in plasma and liver.
Liver impairment	No specific Child-Pugh based dose adjustment; use with caution in severe hepatic impairment.
Pediatric use	2-20 mcg/kg/min IV continuous infusion; titrate to desired effect.
Geriatric use	Start at lower end of dosing range due to decreased renal function and increased sensitivity; monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

MAOIs can cause severe hypertension Extravasation can cause tissue necrosis and sloughing.

Breastfeeding

Dopamine is poorly bioavailable orally and has a short half-life. Excretion into breast milk is minimal; M/P ratio not available. Due to rapid degradation in the infant's gut, systemic effects are unlikely. Considered compatible with breastfeeding.

Teratogenic Risk

Dopamine hydrochloride is a catecholamine with limited human data. Animal studies have not demonstrated teratogenicity at clinically relevant doses. However, during pregnancy, potential fetal risks are primarily secondary to maternal vasoconstriction and reduced uterine blood flow, which may occur at high doses (e.g., >10 mcg/kg/min). No specific trimester-specific risks have been identified; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	hypotension
Serious Effects

Absolute Contraindications

["Hypersensitivity to dopamine or sulfites (if formulated with sulfites)","Pheochromocytoma","Uncorrected tachyarrhythmias or ventricular fibrillation"]

Clinical Precautions

Precautions

["Extravasation risk: may cause tissue necrosis if extravasated; administer via central line if possible.","Correct hypovolemia before use.","May cause tachyarrhythmias and excessive vasoconstriction.","Use with caution in patients with ischemic heart disease or peripheral vascular disease.","May worsen pulmonary hypertension."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…